Novel Metastatic Serous Epithelial Ovarian Cancer (SEOC) Mouse Models, Cell Lines, and Orthotopic Models Useful for Biomarker Discovery and Preclinical Testing

The high mortality rate from ovarian cancers can be attributed to late-stage diagnosis and lack of effective treatment. Despite enormous effort to develop better targeted therapies, platinum-based chemotherapy still remains the standard of care for ovarian cancer patients, and resistance occurs at a high rate. One of the rate limiting factors for translation of new drug discoveries into clinical treatments has been the lack of suitable preclinical cancer models with high predictive value.

NCI CAPR has developed Tri-allelic K18-T121tg/+/Brca1fl/fl/p53fl/fl SEOC GEM Model, GEM-derived SEOC orthotopic mouse model, and biological materials derived therefrom, with several key histopathologic, immunophenotypical, and genetic features of human SEOC. SEOC GEMs were utilized to create orthotopic immunocompetent transplant models, and to generate synchronized cohorts of mice suitable for preclinical studies. NCI CAPR conducted studies that determine these models are tractable for use in routine efficacy studies and demonstrate the utility of these models in evaluating the potential efficacy of novel therapeutics for ovarian cancer.

Potential Commercial Applications: Competitive Advantages:
  • These models serve as a foundation for preclinical research and evaluation of efficacy of novel therapeutics for ovarian cancer.
  • The GEM models described here can be used to develop cell lines and allograft models for evaluating drug potency relative to Brca1 mutation status.
  • These mouse models provide the opportunity for evaluation of effective therapeutics, including prediction of differential responses in Brca1-wild type and Brca1-deficient tumors and development of relevant biomarkers.
  • Novel resource for evaluating disease etiology and biomarkers, therapeutic evaluation, and improved imaging strategies in epithelial ovarian cancer.
  • Similarity to human ovarian cancer based on transcriptional profiling.
  • Suitable preclinical cancer models with high predictive value.


Simone Difilippantonio (NCI)  ➽ more inventions...

Terry Van Dyke (NCI)  ➽ more inventions...

Ludmila Szabova (NCI)  ➽ more inventions...

Chaoying Yin

Yurong Song (NCI)  ➽ more inventions...

Sujata Bupp (NCI)  ➽ more inventions...

Zoe Ohler (NCI)  ➽ more inventions...

Intellectual Property:
Research use – no patent protection will be sought.

Szabova L, et al. PMID 24748377
Szabova L, et al. PMID 22617326

Collaboration Opportunity:

Researchers at the NCI seek licensing and/or co-development research collaborations for the commercialization of agents for the treatment of SEOC. Requests for copies of the patent application or inquiries about licensing, research collaborations, and co-development opportunities should be sent to John D. Hewes, Ph.D., email:

Licensing Contact:
Lauren Nguyen-Antczak, Ph.D., J.D.
Phone: 301-624-8752

OTT Reference No: E-069-2012/0
Updated: Jul 26, 2016